Collegium Pharma Q4 Jornay PM net revenue jumps 57% to USD 45.9 million

Reuters02-26
Collegium Pharma Q4 Jornay PM net revenue jumps 57% to USD 45.9 million

Collegium said Q4 2025 product revenues, net were USD 205.4 million (+13.0%), with GAAP net income of USD 17.0 million and GAAP EPS of USD 0.54 (basic) and USD 0.46 (diluted). Q4 adjusted EBITDA was USD 127.3 million (+18.0%), and cash from operations was USD 123.0 million. For FY 2025, Collegium reported record product revenues, net of USD 780.6 million (+24.0%), GAAP net income of USD 62.9 million and GAAP EPS of USD 1.98 (basic) and USD 1.73 (diluted). FY adjusted EBITDA was USD 460.5 million (+15.0%), and cash from operations was USD 329.3 million. The company ended 2025 with cash, cash equivalents and marketable securities of USD 386.7 million. Jornay PM Q4 net revenue was USD 45.9 million (+57.0%) and FY net revenue was USD 148.9 million (+48.0% vs pro forma 2024); Q4 prescriptions exceeded 200,000 (+16.0%) and Q4 prescribers reached 29,000 (+21.0%). Q4 pain portfolio net revenues were USD 159.6 million (+5.0%), including Belbuca USD 59.1 million (+7.0%), Xtampza ER USD 48.6 million (-6.0%), and the Nucynta franchise USD 47.9 million (+15.0%); FY pain portfolio net revenues were USD 631.7 million (+6.0%). Collegium also highlighted new supply and quality agreements with Hikma tied to its authorized generic arrangement for Nucynta and Nucynta ER, with Nucynta ER expected to launch in Q1 2026, and said it closed a USD 980.0 million syndicated credit facility in December. The company reaffirmed FY 2026 guidance for product revenues, net of USD 805.0 million to USD 825.0 million, Jornay PM revenue, net of USD 190.0 million to USD 200.0 million, and adjusted EBITDA of USD 455.0 million to USD 475.0 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collegium Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602260730PRIMZONEFULLFEED9661644) on February 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment